TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $79.83.

Several brokerages have commented on TMDX. Oppenheimer upped their target price on shares of TransMedics Group from $90.00 to $92.00 in a research report on Friday, August 4th. Morgan Stanley upped their price objective on shares of TransMedics Group from $50.00 to $54.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $67.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, November 7th. TheStreet upgraded shares of TransMedics Group from a “d+” rating to a “c-” rating in a research report on Friday, August 4th. Finally, TD Cowen upped their price objective on shares of TransMedics Group from $95.00 to $110.00 and gave the company an “outperform” rating in a research report on Friday, August 4th.

TransMedics Group Stock Up 2.9 %

NASDAQ:TMDX opened at $68.70 on Monday. The stock’s fifty day moving average price is $51.20 and its two-hundred day moving average price is $67.76. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -62.45 and a beta of 1.63. TransMedics Group has a 52-week low of $36.42 and a 52-week high of $99.63. The company has a debt-to-equity ratio of 4.00, a quick ratio of 10.13 and a current ratio of 10.93.

Insider Activity at TransMedics Group

In other news, Director David Weill bought 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was acquired at an average cost of $62.00 per share, for a total transaction of $155,000.00. Following the purchase, the director now owns 13,693 shares of the company’s stock, valued at approximately $848,966. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other TransMedics Group news, VP Miriam Provost sold 2,708 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $66.52, for a total value of $180,136.16. Following the transaction, the vice president now directly owns 23,611 shares of the company’s stock, valued at approximately $1,570,603.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David Weill purchased 2,500 shares of the stock in a transaction on Tuesday, August 29th. The stock was bought at an average cost of $62.00 per share, for a total transaction of $155,000.00. Following the completion of the acquisition, the director now owns 13,693 shares in the company, valued at $848,966. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 30,208 shares of company stock worth $1,927,986. Insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Huntington National Bank acquired a new stake in shares of TransMedics Group in the second quarter valued at approximately $30,000. Global Retirement Partners LLC acquired a new position in TransMedics Group during the third quarter valued at approximately $38,000. Cutler Group LLC CA raised its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. Ancora Advisors LLC acquired a new position in TransMedics Group during the first quarter valued at approximately $38,000. Finally, First Horizon Advisors Inc. raised its position in TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after purchasing an additional 169 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.